Jaume Bosch receives 2013 Lilly Foundation Biomedical Research Award
The Chair at Idibaps-Hospital Clínic has discovered therapeutic targets that have reduced cirrhosis mortality rates from 50% to 20%.
By Biocat
Dr. Jaume Bosch is one of the winners of the 2013 Lilly Foundation Biomedical Research Awards, specifically in the clinical-research category, for his important work in the field of hepatology, the analysis of portal hypertension and hemodynamic alterations associated with liver disease. Portal hypertension is the leading cause of death and liver transplants among patients suffering from cirrhosis. Dr. Bosch’s contributions have led to the discovery of new therapeutic targets that have led to a drop in cirrhosis-related deaths, down from 50% to less than 20% in the past two decades.
Dr. Bosch is the chair of Medicine at the University of Barcelona, scientific director of the Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd) and head of the unit for liver hemodynamics and portal hypertension and digestive bleeding secondary to ruptured esophageal varicose veins at the August Pi i Sunyer Biomedical Research Institute (Idibaps)-Hospital Clínic. Additionally, he presides over the Spanish Association for the Study of the Liver.
In the preclinical-research category, professor Andrés Moya was recognized for his work in the field of genomics and the evolution of microorganisms. Moya led the sequencing of the first genome carried out exclusively in Spain. He is the scientific director of the Valencian Regional Government Center for Public Health Research (CSISP-FISABIO) and Genetics Chair at the University of Valencia.
The Lilly Foundation Awards, which have been held since 2001 with the aim of contributing to the development of healthcare in the country, have also recognized other important scientists including Xavier Estivill, Josep Maria Gatell, Maria Blasco and Manel Esteller.